| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 2.52▼ | 2.53▼ | 2.53▼ | 2.52▼ | 2.48▲ |
| MA10 | 2.54▼ | 2.56▼ | 2.55▼ | 2.49▲ | 2.34▲ |
| MA20 | 2.57▼ | 2.56▼ | 2.53▼ | 2.45▲ | 3.15▼ |
| MA50 | 2.58▼ | 2.53▼ | 2.49▲ | 2.47▲ | 1.80▲ |
| MA100 | 2.54▼ | 2.50▲ | 2.48▲ | 3.51▼ | 2.00▲ |
| MA200 | 2.49▲ | 2.42▲ | 2.31▲ | 2.04▲ | 7.23▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.008▼ | -0.011▼ | -0.007▼ | 0.021▲ | -0.160▼ |
| RSI | 38.748▼ | 45.026▼ | 47.499▼ | 50.981▲ | 49.722▼ |
| STOCH | 14.824▼ | 17.393▼ | 28.871 | 50.534 | 37.451 |
| WILL %R | -95.455▼ | -96.403▼ | -96.403▼ | -55.208 | -79.630▼ |
| CCI | -107.619▼ | -143.842▼ | -94.872 | -3.306 | -30.596 |
|
Thursday, April 23, 2026 05:25 AM
Non-cardiotoxic anthracycline demonstrates activity where traditional chemotherapies have historically failed, supporting potential expansion of Annamycin into a major unmet-need ...
|
|
Tuesday, April 21, 2026 09:43 PM
Detailed price information for Moleculin Biotech CS (MBRX-Q) from The Globe and Mail including charting and trades.
|
|
Tuesday, April 21, 2026 07:35 AM
Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidate, annamycin, has been accepted for poster ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 27/04/26 | 2.51 | 2.51 | 2.505 | 2.505 | 37,887 |
| 24/04/26 | 2.54 | 2.639 | 2.50 | 2.54 | 99,187 |
| 23/04/26 | 2.47 | 2.5791 | 2.29 | 2.54 | 544,260 |
| 22/04/26 | 2.54 | 2.54 | 2.42 | 2.50 | 57,865 |
| 21/04/26 | 2.57 | 2.5999 | 2.47 | 2.53 | 59,892 |
| 20/04/26 | 2.41 | 2.58 | 2.35 | 2.56 | 109,078 |
| 17/04/26 | 2.44 | 2.4799 | 2.375 | 2.42 | 94,888 |
| 16/04/26 | 2.37 | 2.435 | 2.36 | 2.40 | 108,297 |
| 15/04/26 | 2.455 | 2.46 | 2.37 | 2.44 | 132,207 |
| 14/04/26 | 2.7002 | 2.7002 | 2.445 | 2.49 | 155,297 |
|
|
||||
|
|
||||
|
|